Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type
III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed
that arteries are thin and overloaded in this patients. We test the protective effect of
celiprolol on cardiovascular events in a 5 years, randomized, PROBE design